Advertisement
Advertisement

PCRX

PCRX logo

Pacira BioSciences Inc

19.81
USD
+0.34
+1.75%
Dec 26, 15:59 UTC -5
Closed
...

Pacira BioSciences Inc Profile

About

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.

Info & Links

CEO

Frank D. Lee

Headquarters

5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA, FL 33609, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.pacira.com

Auditor

KPMG LLP

Share holders

11

Employees

712

Pacira BioSciences Inc Statistics

Valuation Measures

Market Capitalization2

914.63M

Enterprise Value

1.26B

Enterprise Value/EBITDA(ttm)

88.56

Price to Earnings Ratio(ttm)

8.47

Price to Sales(ttm)

1.30

Price to Book(mrq)

1.20

Price to Cash(ytd)

4.92

Profitability

Gross Margin(ttm)

74.35%

Operating Margin(ttm)

16.39%

Profit Margin(ttm)

-13.85%

Return on Equity(ttm)

13.42%

Return on Invested Capital(ttm)

-8.91%

Return on Assets(ttm)

7.19%

Income Statement

Revenue(ttm)

694.96M

Revenue Per Share(ttm)

15.05

Gross Profit(ttm)

516.72M

EBITDA(ttm)3

14.18M

Net Income Available to Common(ttm)

-90.73M

Diluted EPS(ttm)

-2.03

Share Statistics

Beta (5Y Monthly)

0.80

52-Week Change

-30.47%

S&P 500 52-Week Change

26.27%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

46.17M

Dividend Yield

0.00%

Float4

43.22M

% Held by Insiders

6.40%

% Held by Institutions

99.73%

Balance Sheet

Total Cash(mrq)

453.81M

Total Cash Per Share(mrq)

9.83

Total Debt(mrq)

587.36M

Total Debt/Equity(mrq)

78.36%

Current Ratio(mrq)

2.25%

Quick Ratio(mrq)

1.89%

Book Value Per Share(mrq)

16.24

Cash Flow

Operating Cash Flow Per Share(ytd)

3.39

Free Cash Flow(ytd)

147.74M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement